Roman A Knyazev¹*, Alexander V Ryabchenko¹, Wu Naishi², Maria V Kotova, Natalia V Trifonova¹, Lev M Polyakov¹ and Mikhail I Voevoda¹

¹Federal Research Center for Fundamental and Translational Medicine, Novosibirsk, Russia
²The Department of Cardiovascular Surgery, Tianjin Medical University General Hospital, China

*Corresponding Author: Roman A Knyazev, Federal Research Center for Fundamental and Translational Medicine, Novosibirsk, Russia.

Received: May 02, 2023; Published: May 26, 2023

Abstract

The study tries to solve the problem related to the development of new transport forms of anticancer drugs.

The methods of fluorescence quenching and gel filtration have shown that the recombinant apolipoprotein A-I obtained by us has the ability to form a stable complex with doxorubicin. The calculated value of the association constant of the complex confirms the possibility of using the recombinant аpolipoprotein A-I as a transport form into tumor cells. The number of molecules of the anticancer drug bound per protein molecule represents a wide range of dosage adjustment. Proven ability of recombinant apolipoprotein A-I c doxorubicin penetrate into cytoplasm and nucleus of Ehrlich ascites carcinoma cells.

The results obtained make it possible to consider the real possibility of using recombinant apolipoprotein A-I as a transport form of doxorubicin.

 Keywords: Recombinant Apolipoprotein A-I; Transport form of Anticancer Drugs; Ehrlich's Ascites Carcinoma; Chemotherapy; Doxorubicin

References

1. Naz S., et al. “Advances in Therapeutic Implications of Inorganic Drug Delivery Nano-Platforms for Cancer”. International Journal of Molecular Sciences4 (2019): 965.
2. Remesh Ambili. "Toxicities of anticancer drugs and its management". International Journal of Basic & Clinical Pharmacology 1 (2012): 2-12.
3. Basak Debasish., et al. “Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile". Life1 (2021): 48.
4. Park JH., et al. “Targeted delivery of low molecular drugs using chitosan and its derivatives”. Advanced Drug Delivery Reviews1 (2010): 28-41.
5. Yihan Yao., et al. “Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance”. Frontiers in Molecular Biosciences (2020): 7.
6. Amreddy N., et al. “Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery”. Advances in Cancer Research 137 (2018): 115-170.
7. Mitchell MJ., et al. “Engineering precision nanoparticles for drug delivery”. Nature Reviews Drug Discovery 20 (2021)101-124.
8. Hirsjarvi Samuli., et al. “Passive and active tumour targeting with nanocarriers". Current Drug Discovery Technologies3 (2011): 188-196.
9. Manhas Daljeet Singh. "Passive and active tumor targeting of nano carriers for anti-cancer drug delivery-a review". Indo American Journal of Pharmaceutical Sciences11 (2016): 1345-1349.
10. Pourmousa Mohsen., et al. “Tertiary structure of apolipoprotein AI in nascent high-density lipoproteins". Proceedings of the National Academy of Sciences20 (2018): 5163-5168.
11. DC Chan., et al. “Apolipoproteins as markers and managers of coronary risk”. QJM: An International Journal of Medicine 5 (2006): 277-287.
12. Polyakov LM and Panin LYe. “High-density lipoproteins and apolipoprotein A-I: regulatory role and new therapeutic strategies for the treatment of atherosclerosis”. Atherosclerosis (Russia) 1 (2013): 42-53.
13. Torchilin VP. “Passive and Active Drug Targeting: Drug Delivery to Tumors as an Example”. Drug Delivery 197 (2010)3-53.
14. Wohlfart S., et al. “Transport of drugs across the blood–brain barrier by nanoparticles”. Journal of Controlled Release 2 (2012): 264-273.
15. Leiva A., et al. “Mechanisms regulating hepatic SR-BI expression and their impact on HDL metabolism”. Atherosclerosis 2 (2011): 299-307.
16. Carballo-Jane Ester., et al. “ApoA-I mimetic peptides promote pre-β HDL formation in vivo causing remodeling of HDL and triglyceride accumulation at higher dose". Bioorganic and Medicinal Chemistry 24 (2010): 8669-8678.
17. Vasquez Marcos., et al. “Exploiting scavenger receptors in cancer immunotherapy: Lessons from CD5 and SR‐B1". European journal of immunology 7 (2017): 1108-1118.
18. Yuan B., et al. “High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in breast cancer”. Tumour Biology 37 (2016): 3581-3588.
19. Schorghofer D., et al. “The HDL receptor SR-BI is associated with human prostate cancer progression and plays a possible role in establishing androgen independence”. Reproductive Biology and Endocrinology 1 (2015): 1-10.
20. Gusev EYu., et al. “Physiological and pathogenetic role scavenger receptors in humans”. Medical Immunology (Russia) 1 (2020): 7-48.
21. Knyazev RA., et al. “Study of the ability of high density lipoproteins and apolipoprotein A-I to bind and transport anticancer drugs into the cells of Ehrlich's ascites carcinoma”. International Journal of Applied and Fundamental Research 11 (2015): 538-542.
22. Makwana Vivek., et al. “Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization". International Journal of Pharmaceutics 593 (2021): 120117.
23. Maryam Zamanian-Daryoush and Joseph A DiDonato. “Apolipoprotein A-I and Cancer”. Experimental Pharmacology and Drug Discovery 6 (2015): 265.
24. Ryabchenko AV., et al. “Production and analysis of biological properties of recombinant human apolipoprotein A-I”. Bulletin of Experimental Biology and Medicine1 (2015): 129-133.
25. Ryabchenko AV., et al. “The use of modified variants of recombinant apolipoprotein A-I as conveyors of small interface RNA into tumor cells”. Siberian Scientific Medical Journal6 (2018): 29-34.
26. Ghisaidoobe ABT and Chung SJ. “Intrinsic tryptophan fluorescence in the detection and analysis of proteins: a focus on Förster resonance energy transfer techniques”. International Journal of Molecular Sciences12 (2014): 22518-22538.
27. Polyakov LM., et al. “The analysis of interaction lipoproteins and steroid hormones”. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry 4 (2010): 362-365.
28. Lakowicz JR. “Principles of Fluorescence Spectroscopy”. 3^rd/Spinger: Berlin/Heidelberg, Germany, (2006): 964.
29. Strober W. “Trypan blue exclusion test of cell viability”. Current Protocols in Immunology 1 (2015): A3-B.
30. Lommen J., et al. “Release kinetics of the model protein FITC-BSA from different polymer-coated bovine bone substitutes”. Head Face Medicine 15 (2019): 1-3.
31. Yammine A., et al. “Tryptophan Fluorescence Quenching Assays for Measuring Protein-ligand Binding Affinities: Principles and a Practical Guide”. Bio-protocol11 (2019): e3253.

Citation

Citation: Roman A Knyazev., et al. “Recombinant Apolipoprotein A-I Is Able Bind and Transport Doxorubicin into Ehrlich Carcinoma Cells". Acta Scientific Pharmaceutical Sciences 7.6 (2023): 48-54.

Copyright

Copyright: © 2023 Roman A Knyazev., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.